News

News Jul 11, 2025

This Week in Drug Pricing: Patients Joins HHS for a Drug Prices Roundtable, Lowering Drug Prices Doesn’t Hurt Innovation, Tariffs Are Back. And They’re Still a Bad Idea, and ICYMI

Last week, five P4AD Patient Advocates participated in a roundtable with HHS Secretary Kennedy and NIH Director Bhattacharya, focused on the burden of high drug prices and the administration’s…

Read Article News Jul 3, 2025

This Week in Drug Pricing: Pharma Handouts, Not Patient Relief: Congress Passes The ORPHAN Cures Act, PhRMA Panics as “Most Favored Nation” Pricing Gains Traction, and ICYMI

Today, the House passed a reconciliation bill that includes a nearly $5 billion giveaway to the pharmaceutical industry: the ORPHAN Cures Act, just a day after the Senate passed the same legislation…

Read Article News Jun 26, 2025

This Week in Drug Pricing: Investors- and Lawmakers – Aren’t Buying Pharma’s “Warnings”, Pharma Front Groups Working Overtime For Big Drug Companies, and P4AD Patient Advocate Speaks Up in New Op-Ed

New reporting from POLITICO reveals that lawmakers from both parties have been snapping up stocks in the 13 largest U.S. pharma companies in recent weeks — all while the drug industry ramps up its…

Read Article News Jun 20, 2025

This Week in Drug Pricing: Patient Victory: ORPHAN Cures Act Excluded from Reconciliation Text, I-MAK Releases New Report on Pharma Patent Abuse, and ICYMI

This week, patients scored a key victory as the Senate Finance Committee released reconciliation text that excluded the harmful ORPHAN Cures Act – a pharma-backed proposal that would have weakened…

Read Article News Jun 13, 2025

This Week in Drug Pricing: P4ADNOW and AARP Send Letter on OPRHAN Cures to Senate, Most Favored Nation: One Month Out, Spotlight on Cell and Gene Therapies, and ICYMI

To safeguard hard-fought and cost-saving drug price reforms, P4ADNow and AARP sent a joint letter to all Senators to oppose the inclusion of the ORPHAN Cures Act in the reconciliation bill.

Read Article News Jun 6, 2025

This Week in Drug Pricing: Fighting ORPHAN Cures in the Senate, The Tide Continues to Turn Against PBMs, Supporting Transparency in Drug Advertisements on Capitol Hill, and ICYMI

As the Senate considers the House-passed reconciliation package, P4ADNow is urging lawmakers to reject the inclusion of the ORPHAN Cures Act — an unnecessary Pharma handout that would weaken the…

Read Article News May 30, 2025

This Week in Drug Pricing: Expanding Medicare Negotiation with the SMART Prices Act, Trump’s “Most Favored Nation” Proposal Keeps Moving, and RFK Jr. vs. Big Pharma’s TV Ads

The Strengthening Medicare and Reducing Taxpayer (SMART) Prices Act has been re-introduced by Senators Amy Klobuchar (D-MN) and Peter Welch (D-VT) — legislation that will expand Medicare price…

Read Article News May 23, 2025

This Week in Drug Pricing: P4AD Report Exposes Pharma-Funded Groups Doing the Industry’s Bidding, Centering Patient Stories at CHCI, and The ORPHAN Cures Act Will Cost Taxpayers Billions

As the fight to lower drug prices heats up on Capitol Hill, P4AD released a new report, The Rampant Reach of Pharma’s Hidden Hand, uncovering the pharmaceutical industry’s efforts to fund, influence…

Read Article News May 16, 2025

This Week in Drug Pricing: Trump Revives Global Drug Pricing Debate, Another Win for Patients and Another Warning For Big Pharma In Court, The ORPHAN Cures Act Would Undermine Patient Savings, Endorsing the No Handouts for Drug Advertisements Act, and ICYMI

This week, President Trump issued an Executive Order (EO) focused on addressing the high cost of prescription drugs.

Read Article News May 9, 2025

This Week in Drug Pricing: Growing Momentum Around International Reference Pricing, P4AD Holds Community Town Hall, Drug Spending Hits Record High As Patients Struggle to Afford Medications, and ICYMI

Senators Josh Hawley (R-MO) and Peter Welch (D-VT) unveiled a bipartisan bill that would bar drug companies from charging Americans more than the international average price for a specific…

Read Article